Form 4: Aptevo Therapeutics Inc. Executive Acquires Restricted Stock Units

Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics Inc., reports acquisition of restricted stock units convertible to common stock.

Summary

• Jeffrey G. Lamothe, EVP, COO of Aptevo Therapeutics Inc., filed a Form 4.
• The form reports a transaction on July 17, 2024, where Lamothe acquired 12,825 Restricted Stock Units (RSUs).
• These RSUs convert into common stock on a one-for-one basis.
• The RSUs vest in three approximately equal annual installments beginning on July 17, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of executive compensation. The vesting schedule suggests a long-term commitment.

Positives

• The acquisition of RSUs by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates compensation in the form of stock awards.

Stakeholder Impact

• Shareholders may view the RSU grant as an incentive for the executive to drive long-term value.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates

Keywords

Aptevo Therapeutics, Form 4, Restricted Stock Units, RSU, Jeffrey G. Lamothe, EVP, COO, Beneficial Ownership, Securities